Figure 5
Evaluation of in vivo therapeutic activity of FTY720 and milatuzumab in the preclinical MCL model. SCID mice were injected intravenously with 40 × 106 JeKo cells and observed daily for signs of tumor burden. The median survival for FTY720- and milatuzumab-treated mice (n = 10) was 36 days (95% CI, 31-36) compared with 31 days for the FTY720-treated mice (95% CI, 28-32) and 33.5 days for the milatuzumab-treated mice (95% CI, 23-34).
